Journal of Cardiac Failure DOI: https://doi.org/10.1016/j.cardfail.2014.01.019
Rebecca S. Boxer, MD, MS MD, MS Rebecca S. MD, MS Rebecca S. Boxer, Brian D. Hoit, MD, Brian J. Schmotzer, MS, Gregory T. Stefano, MD, Amanda Gomes, MSc, MD, Lavinia Negrea, MD
- 50,000 IU of vitamin D weekly following cardiac failure helps – RCT 2014
- Getting Vitamin D before heart surgery prevented Afib in those who had been deficient – July 2018
- 50,000 IU of Vitamin D for 9 weeks was enough to restore blood levels (but not long enough to statistically improve CVD) – Aug 2018
- Cardiovascular risk markers not helped by 20,000 IU of vitamin D weekly – RCT May 2018
- Hypertension not controlled by 26 ng of Vitamin D (50,000 IU bi-weekly A-A) – RCT Nov 2017
- Angina dramatically reduced by injections of vitamin D twice a month (300,000 IU) – Jan 2015
Cardiovascular category starts with the following
- Overview Cardiovascular and vitamin D
- Hypertension and vitamin D
- Overview Metabolic Syndrome and vitamin D
- Overview Stroke and vitamin D
- Heart Attack 647 items as of May 2018
- Arrhythmia OR “atrial fibrillation” 497 items as of May 2018
- (Arrhythmia OR “atrial fibrillation”) AND Magnesium 345 items as of May 2018
- "C-Reactive Protein" 1530 items as of June 2019
- TRIGLYCERIDES 863 items as of May 2018
- "Peripheral Artery Disease" 170 items as of July 2019
- "Sudden Cardiac Arrest" 98 items as of May 2018
- Search VitaminDWiki for CHF or "HEART FAILURE" 1220 items as of Aug 2017
- Search VitaminDWiki for Atherosclerosis 1510 items as of July 2019
- Cholesterol is needed to produce both Vitamin D and Cortisol
- Overview Cholesterol and vitamin D
- Statins and vitamin D statins often reduce levels of vitamin D
Background: Vitamin D deficiency is associated with heart failure (HF) events, and in animal models vitamin D down-regulates renin-angiotensin-aldosterone system hormones.
Methods: Patients with New York Heart Association (NYHA) functional class II–IV HF and a 25OH-D level ≤37.5 ng/mL received 50,000 IU vitamin D3 weekly (n = 31) or placebo (n = 33) for 6 months. Serum aldosterone, renin, echocardiography, and health status were determined at baseline and 6 months.
Mean age of participants was 65.9 ± 10.4 years, 48% were women, 64% were African American, mean ejection fraction was 37.6 ± 13.9%, 36% were in NYHA functional class III, and 64% were in class II. The vitamin D group increased serum 25OH-D (19.1 ± 9.3 to 61.7 ± 20.3 ng/mL) and the placebo group did not (17.8 ± 9.0 to 17.4 ± 9.8 ng/mL).
Aldosterone decreased in the vitamin D group (10.0 ± 11.9 to 6.2 ± 11.6 ng/dL) and not in the placebo group (8.9 ± 8.6 to 9.0 ± 12.4 ng/dL; P = .02). There was no difference between groups in renin, echocardiographic measures, or health status from baseline to 6 months. Modeling indicated that variables which predicted change in aldosterone included receiving vitamin D, increasing age, African American race, and lower glomerular filtration rate.
Vitamin D3 repletion decreases aldosterone in patients with HF and low serum vitamin D. Vitamin D may be an important adjunct to standard HF therapy. Further study will assess if vitamin D provides long-term benefit for patients with HF.